DRIVING PROGRESS IN OBESITY CLINICAL RESEARCH

Patient-Centric Solutions for Obesity Clinical Research


20+

Years of experience in obesity clinical research

425+

Clinical studies completed for diseases across the metabolic continuum  

20

Contributions to 20 approved metabolic drugs and devices

Specialized expertise to accelerate obesity drug development

As the foremost clinical research provider specializing in the continuum of metabolic diseases, we have made significant contributions to obesity clinical research over the past two decades. ProSciento provides scientific and operational expertise in the design and management of all facets of obesity-related clinical research and development.

Team Member with deep scientific  experience

Patient and Site Engagement in Obesity Clinical Trials

doctor with graphical representation of data

Our data-driven recruitment strategies ensure enrollment of eligible patients at highly qualified sites for obesity trials, enhancing engagement and retention. ProSciento’s global network of clinical trial sites, supported with proven engagement solutions and advanced technologies, streamlines operations, boosts efficiency, and increases enrollment and retention, ensuring a positive experience.

Multifaceted Expertise Beyond Obesity

Working with a CRO focused on diseases across the metabolic continuum is critical. Obesity-associated pathophysiology extends beyond the metabolic and endocrine actions of white and brown adipocytes to the gastrointestinal tract and the brain’s role in maintaining energy homeostasis. Comorbidities are often associated with obesity, including type 2 diabetes, cardiovascular risk factors, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

physician gathering information from patient

Examine our metabolic compound and device experience

SMALL MOLECULES

Insulin secretagogues
Sulfonylureas, meglitinides, glucokinase activators, GPR40, GPR119, GPR44 agonists
Insulin sensitizers 
Biguanides, PPAR agonists, SARMs, SIRT1 activators, 11beta-HSD1 inhibitors
Incretin/glucagon pathway modulators
Dipeptidyl peptidase-4 inhibitors, glucagon-receptor antagonists
SGLT-2 Inhibitors
Other oral agents
Diacylglycerol acyltransferase and ACC inhibitors, thyroid hormone receptor beta (TRβ) agonists, farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor, niacin derivatives, CCR2 antagonists, ileal bile acid transport (IBAT) inhibitors, PDF4 inhibitors, de novo lipogenesis (DGAT, SCD1 & ACC) inhibitors, cannabinoid 1 receptor modulator

BIOLOGICS

Insulins
Ultra-rapid, rapid-, long- and ultra-long acting NCEs, biosimilar insulins, inhaled and oral insulins
Incretins mimetics
Incretins (GLP-1, GIP, GCGR), mono, dual and triple agonists, oxyntomodulin analogs
Other glucoregulatory peptides & proteins
Amylin analogues, peptide YY (3-36), fibroblast growth factors (FGF21), insulin-like growth factor 1
Immune-modulation & beta cell regeneration
Monoclonal antibodies, islet neogenesis associated protein (INGAP)  

OLIGONUCLEOTIDES 

miRNA-based therapeutics

DEVICES

Artificial pancreas
Continuous glucose monitoring systems
Alternative routes of peptide administration
mHealth applications

latest resources | obesity


Partner with Prosciento

ProSciento’s science-driven approach provides clients seamless support from early development strategy to decision milestones.

Collaborating with us ensures interactions with a team of experts, focused on tailoring services to suit your individualized metabolic continuum program needs.

chat bubble icon Speak with an Expert

ProSciento team members